AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 43 min read$UTHR

United Therapeutics (NASDAQ:UTHR) beats Q3 2026 sales expectations, stock soars

United Therapeutics (UTHR) reported Q3 2026 revenue of $832.5M, beating estimates by 6.4% but missing EPS expectations. Revenue grew 4.1% YoY, while operating margin declined to 37%. The company's stock surged 5.9% post-results. Analysts expect 4.5% revenue growth over the next 12 months, with EPS projected to rise 10.1%.

Original reporting
finance.yahoo.com
Published Nov 4, 2026, 11:50 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
United Therapeutics (NASDAQ:UTHR) beats Q3 2026 sales expectations, stock soars — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$UTHRNeutralHigh
01

Why it matters

The earnings release provides new data that moved the stock 5.9% higher, indicating immediate market impact.

02

Market read

First-report earnings disclosure for a mid-cap biotech, with a notable price move, making it a high‑value trading article.

03

What to watch

Margin compression and rising expenses may signal longer-term profitability challenges.

Relevance 8/10Novelty 8/10Timing: after-hours reaction

Background

United Therapeutics reported Q3 2026 results with revenue of $832.5M beating consensus and GAAP EPS of $5.71 missing estimates.

Company-level read

Ticker impact

$UTHRNeutralHigh confidence
Context

Q3 2026 earnings released, revenue beat estimates while EPS missed, causing a 5.9% stock surge.

Expected impact

potential pressure as market prices in the earnings miss despite the revenue beat

Evidence & confidence

The report provides fresh earnings numbers; investors reacted positively to revenue but are wary of the profit shortfall.

Market effects

Sector

Healthcare biotech sector may see modest rally on revenue beat, but earnings miss could temper enthusiasm.

Regional

U.S. market focus on biotech earnings, limited broader regional effect.

Global

Limited to investors tracking U.S. biotech earnings.

Counterpoint

What could challenge this read

Despite the EPS miss, the strong revenue beat and growth outlook could justify a buy on the dip.

Key entities

  • Executive
    Martine Rothblatt

    Chairperson and CEO of United Therapeutics, quoted on growth outlook.

Read at source← All news

StoryUnited Therapeutics reports Q3 2026 earnings miss despite revenue beat

Also covered by

3 outlets

Related articles

NOV 4
$UTHRMedAI 8/10

United Therapeutics Q3 2026 Revenue Up 4%, Net Income Falls 24%

United Therapeutics (UTHR) reported Q3 2026 revenue of $832.5M, up 4% YoY, but net income fell 24% to $258.6M due to higher R&D spending and competitive pressures. EPS declined 20% to $5.71. Tyvaso DPI sales rose 13%, while nebulized Tyvaso fell 12%. R&D expenses surged 119% to $279.2M, partly due to the Thymmune acquisition. The company repurchased shares under a 10b5-1 plan and a $2B repurchase program.

minichart.com.sg2 min
NOV 4
$UTHRHigh

United Therapeutics buys out Pfizer royalty for $525 million

United Therapeutics (UTHR) will pay $525M to Pfizer's Arena subsidiary to end royalty obligations on ralinepag, a drug for pulmonary arterial hypertension. The FDA is reviewing an application for oral ralinepag, with a decision expected by June 24, 2027. United Therapeutics acquired rights to ralinepag in 2018 and is also developing an inhaled version. According to the company, the transaction reflects confidence in the drug's revenue potential.

investing.com1 min